Plain-English translation of NCT07672405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for drug-sensitive tuberculosis using a combination of three medications: , , and . Researchers want to find out whether giving a higher starting dose of for the first 4 weeks works better than using a standard dose throughout the entire 17-week treatment course. The goal is to determine the safest and most effective way to treat this form of tuberculosis.
Current tuberculosis treatments take a long time and can have significant side effects. This trial is exploring whether the new medication , combined with two other drugs, can shorten treatment and improve outcomes for people with drug-sensitive tuberculosis.
You likely qualify if…
You likely don't qualify if…
You would visit the study center for a screening appointment up to 11 days before starting treatment. Once enrolled, you would take the three-drug combination once daily for 17 weeks total—either with a higher starting dose for the first month that then decreases, or with a consistent dose throughout. You would have regular follow-up visits during and after treatment, including a 52-week follow-up period after you finish the medication to monitor your health and response to treatment.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
South Africa